KDM4A promotes NEPC progression through regulation of MYC expression [ChIP-seq]

Neuroendocrine prostate cancer (NEPC) represents one of the most lethal forms of prostate cancer (PCa) and lacks life-prolonging treatment. Incidence NEPC is increased due to the widespread use of AR pathway inhibitors (ARPIs) in the treatment of non-metastatic CRPC and hormone-sensitive metastatic tumors. Here we identified histone lysine demethylase KDM4A as a key player in NEPC progression and an effective therapeutic target. We performed ChIP-seq to identify KDM4A target genes in human NEPC cell line 144-13. Overall design: Chromatin immunoprecipitation DNA-sequencing (ChIP-seq) for KDM4A in 144-13 cells.